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None of the lumiracoxib regimens were significantly different
from placebo in terms of change from baseline for systolic or
diastolic blood pressure after 1 or 3 months. In addition, no dose-
response was observed. Adjustment for prognostic risk factors
(age, baseline systolic BP, history of hypertension, or prior use of
anti-hypertensive treatment) had no statistically significant effect
on the results.
Conclusions: This BP meta-analysis including data from 9,611
patients with arthritis demonstrated that lumiracoxib (100 - 400
mg once a day) had a BP profile (both systolic and diastolic)
comparable to patients receiving placebo.
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Purpose: We found previously that hylan G-F 20, a cross-linked
high Mw hyaluronan, improved the cartilage structure in a rabbit
instability model of osteoarthritis (OA) at 1-week post treatment
regimen. In this study, we aimed to examine the sustainability
of the chondro-protective effect and the molecular mechanism
involved.
Methods: New Zealand White rabbits underwent either anterior
cruciate ligament transection (ACLT) or sham surgery. Four-
wk later, 3-weekly injections were performed in the operated
knee of 0.5 ml of hylan G-F 20 (8 mg/ml) or Lactated Ringer’s
Solution (LRS). Animals were sacrificed at 4-wk and 8-wk after
the last injection. Mankin scoring system was used to evaluate
the histological changes in cartilage. The cartilage structure
and the PG content were also examined separately using a
relative quantitative Carlson scoring system. The formation of
osteophytes was quantified by tracing the osteophyte area in
the trochlear ridge using MetaMorph image analysis of gross
morphological photos. RNA was isolated from cartilage and
synovium at 1-wk after the last injection and analyzed using
real-time PCR with rabbit specific primers.
Results: At 4-wk time point, the disease group (ACLT + LRS) de-
veloped severe OA, as shown by the significantly higher Mankin
score, Carlson cartilage score, and Carlson PG score than the
sham group (p<0.0001). There was no significant difference in
Mankin score and Carlson PG score between the OA groups
treated with or without hylan. However, hylan treated OA group
had a significant lower (better) Carlson cartilage structure score
(8.0 vs. 9.7; p = 0.0119; n = 10) and smaller osteophytes (1.42
x 107 vs. 3.58 x 107 pixels; p< 0.05) than the OA control. At
8-wk, the 3 scores of the OA control group were higher (worse)
than those at 4-wk; no significant difference was observed be-
tween hylan treated and non-treated OA groups. To explore the
mechanism of the chondro-protective effect of hylan G-F 20,
we examined the expression of several genes involved in carti-
lage matrix metabolism. The mRNA levels of type I (Col I) and
II collagen (Col II) were increased in OA cartilage compared
with sham control, which were further increased in hylan treated
OA cartilage. The ratio of Col II/Col I was lower in both non-
treated and treated OA cartilage than normal cartilage (control
= 199, OA = 25, and OA + hylan = 19), reflective of the de-
generative nature of OA. MMP13 was increased in OA cartilage
by >10-fold, and similar levels were detected in hylan-treated
cartilage. Significantly, MMP16 was identified as one of the
hylan-responsive genes that were altered in the OA cartilage
and synovium and were changed back toward normal in hylan
treated tissues. IL-1β mRNA levels were low or undetectable in
cartilage in control, OA, and OA + hylan. Low levels of IL-1β were
detected in the synovium, but the levels were unaltered across
the groups.
Conclusions: Three weekly IA injections with hylan G-F 20 im-
proved the integrity of cartilage structure, but not the PG content,
in a rabbit ACLT model of OA. This chondro-protective effect
was observed as early as 1-wk, sustained at 4-wk, and unde-
tectable at 8-wk post-treatment. Our findings of type II collagen
up-regulation and MMP16 down-regulation in hylan-treated joint
tissues suggest that hylan may protect the cartilage structure
by both stimulating the repair and inhibiting the degradation
processes at the molecular level. We also found that hylan treat-
ment reduced osteophyte formation in this rabbit model. Whether
these effects contribute to clinically reported long-term pain relief
associated with hylan G-F 20 requires further investigation. Anal-
yses of the genes that may contribute to OA pain are currently
underway.
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Purpose: An advanced WOMAC index - with two new subscales
as sport/recreation (SP) and quality of life (QL) - KOOS (Knee
Injury and Osteoarthritis Outcome Score) was recently proposed
also for population studies (EM Roos et al. 2006).
Aim: To investigate changes of KOOS in monitoring the sub-
jects with early knee osteoarthritis after different time intervals -
repeated measurements from one month on to 3 years.
Methods: Subjects were females selected from symptomatic
Elva cohort with early knee osteoarthritis. Their mean age was
45 years (35-54 yrs). Nine women passed the exercise therapy
(ExT) program with duration of 3 years (group I) when KOOS was
registrated monthly. Other 9, matched by sex, age and KOOS
basal values, formed the non-exercise therapy control (II) group.
All others (group III, n = 88), were tested before and after the 3
yrs period. KOOS has the following subscales Symptoms, Pain,
Activities of daily life, ADL, Sport and recreation, SP/Rec and
Quality of life, QL. Ten points in all KOOS subscales was taken
as clinically significant change. Besides the KOOS questionnaire
all subjects filled in standard VAS for pain and passed functional
tests for both knees. OA grade was diagnosed by radiographs:
axial for patello- and AP for tibiofemoral joint. At the baseline
radiographic grade I OA was found in 55% of cases, grade II in
9% and grade III in 2% of cases. For statistics the Mann-Whitney
test, the Spearman rank correlations, sign test and time series
analysis were used.
Results: In group I (ExT) and II (controls) registrated KOOS
subcsales no significant changes were observed at baseline.
Large individual fluctuations (up to +50/-50) were observed in
group I during the ExT. Also some relapses were observed
during the long period of ExT. Therefore, individual approach
is needed to use regular KOOS in ExT. The ExT reduced pain,
improved Sp/Rec and ADL, lesser extent - QL. The subgroup with
(IA) and without (IB) improvement of the quality of life (QL) was
find out.At the same time in the non-exercise therapy controls
significantly diminished SP/Rec and QL. After 3 years in the
group III significant changes were observed in two subscales:
more Symptoms (p < 0.05), more limitations in demanding knee
